Acute Stroke Unit, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow G11 6NT, UK.
BMJ. 2010 Nov 23;341:c6046. doi: 10.1136/bmj.c6046.
To assess effect of age on response to alteplase in acute ischaemic stroke.
Adjusted controlled comparison of outcomes between non-randomised patients who did or did not undergo thrombolysis. Analysis used Cochran-Mantel-Haenszel test and proportional odds logistic regression analysis.
Collaboration between International Stroke Thrombolysis Registry (SITS-ISTR) and Virtual International Stroke Trials Archive (VISTA).
23 334 patients from SITS-ISTR (December 2002 to November 2009) who underwent thrombolysis and 6166 from VISTA neuroprotection trials (1998-2007) who did not undergo thrombolysis (as controls). Of the 29 500 patients (3472 aged >80 ("elderly," mean 84.6), data on 272 patients were missing for baseline National Institutes of Health stroke severity score, leaving 29 228 patients for analysis adjusted for age and baseline severity.
Functional outcomes at 90 days measured by score on modified Rankin scale.
Median severity at baseline was the same for patients who underwent thrombolysis and controls (median baseline stroke scale score: 12 for each group, P=0.14; n=29 228). The distribution of scores on the modified Rankin scale was better among all thrombolysis patients than controls (odds ratio 1.6, 95% confidence interval 1.5 to 1.7; Cochran-Mantel-Haenszel P<0.001). The association occurred independently among patients aged ≤80 (1.6, 1.5 to 1.7; P<0.001; n=25 789) and in those aged >80 (1.4, 1.3 to 1.6; P<0.001; n=3439). Odds ratios were consistent across all 10 year age ranges above 30, and benefit was significant from age 41 to 90; dichotomised outcomes (score on modified Rankin scale 0-1 v 2-6; 0-2 v 3-6; and 6 (death) v rest) were consistent with the results of the ordinal analysis.
Outcome in patients with acute ischaemic stroke is significantly better in those who undergo thrombolysis compared with those who do not. Increasing age is associated with poorer outcome but the association between thrombolysis treatment and improved outcome is maintained in very elderly people. Age alone should not be a barrier to treatment.
评估年龄对急性缺血性脑卒中患者对阿替普酶反应的影响。
对接受或未接受溶栓治疗的非随机患者的结局进行调整后的对照比较。分析采用 Cochran-Mantel-Haenszel 检验和比例优势逻辑回归分析。
国际卒中溶栓登记处(SITS-ISTR)与虚拟国际卒中试验档案(VISTA)之间的合作。
23334 例来自 SITS-ISTR(2002 年 12 月至 2009 年 11 月)的接受溶栓治疗的患者和 6166 例来自 VISTA 神经保护试验(1998 年至 2007 年)的未接受溶栓治疗的患者(作为对照组)。在 29500 例患者中(年龄>80 岁的患者 3472 例(“老年人”,平均 84.6 岁),有 272 例患者的基线 NIH 卒中严重程度评分数据缺失,因此,在调整年龄和基线严重程度后,对 29228 例患者进行了分析。
采用改良 Rankin 量表评分评估 90 天的功能结局。
溶栓治疗患者和对照组的基线严重程度中位数相同(中位数基线卒中量表评分:每组 12 分,P=0.14;n=29228)。所有溶栓治疗患者的改良 Rankin 量表评分分布均优于对照组(优势比 1.6,95%置信区间 1.5 至 1.7;Cochran-Mantel-Haenszel P<0.001)。这一关联在≤80 岁的患者中独立存在(1.6,1.5 至 1.7;P<0.001;n=25789)和>80 岁的患者中也存在(1.4,1.3 至 1.6;P<0.001;n=3439)。所有>30 岁的 10 个年龄范围内的比值比均一致,且 41 岁至 90 岁之间的获益显著;二分结局(改良 Rankin 量表评分 0-1 v 2-6;0-2 v 3-6;和 6(死亡)v 其余)与有序分析的结果一致。
与未接受溶栓治疗的患者相比,急性缺血性脑卒中患者接受溶栓治疗的结局明显更好。年龄增长与预后较差相关,但溶栓治疗与改善预后之间的关联在非常高龄患者中仍然存在。年龄本身不应成为治疗的障碍。